Contributions of hyperactive mutations in Mpro from SARS-CoV-2 to drug resistance
J. M. Flynn, S. N. Zvornicanin, A. M. Shaqra, N. Kurt Yilmaz, S. Moquin, D. Dovala, C. A. Schiffer, D. Bolon
This study identifies hyperactive mutations in SARS-CoV-2 Mpro that increase enzyme activity and contribute to drug resistance, finding them more prevalent than binding-reducing mutations.
bioRxiv · Sep 28, 2023 · PreprintBiochemistry